Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?

Table 2

Selected HDAC inhibitors: structural class, compound, isotype selectivity, and study phase—an overview (according to Batty et al. [14] and Schneider-Stock and Ocker [81]).

Structural	HDAC inhibitor (synonyms, abbreviation, supplier)	Class selectivity	Study phase
Hydroxamic acids	m-carboxycinnamic acid bis-hydroxamide (CBHA)
	Oxamflatin
	Belinostat (PXD-101, Curagen Corp/TopoTarget A/S)	I, IIa, IIb, IV	II
	Pyroxamide		I
	Scriptaid
	Superoylamilide hydroxamic acid (SAHA, Vorinostat)	I, IIa, IIb, IV	FDA approval (CTCL)
	Trichostatin A (TSA)	I, II
	Panobinostat (LBH-589; Novartis AG)	I, IIa, IIb, IV	II
Cyclic tretapeptides	Apicidin	I, II
	Romidepsin (FK-228, FR-901228; Gloucester Pharmaceuticals Inc)	I, II	II
	Trapoxin-histone acetylase (TPX-HA) analog (CHAP)
	Trapoxin
Benzamides	Tacedinaline (CI-994; Pfizer Inc)
	Entinostat SNDX-275 (MS-275; Syndax Pharmaceuticals Inc)	I, II	II
Short-chain fatty acids	Butyrate	I, IIa	I
	Valproic acid	I, IIa	I